Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors

The study explores the aberrant activation of the Hedgehog (Hh) signaling pathway in cutaneous melanoma and assesses the therapeutic potential of pharmacological inhibitors like sonidegib and vismodegib. Researchers found that melanoma cells exhibit chronic Hh activation, primarily through a ligand-dependent autocrine mechanism, with significant upregulation of GLI2 and downregulation of PTCH1 and SUFU. Inhibiting the Hh pathway with SMO inhibitors reduced melanoma cell proliferation, migration, and interaction with the tumor microenvironment. Sonidegib showed higher cytotoxicity due to its greater plasma membrane permeability. The study suggests that targeting the Hh pathway could be a promising strategy for melanoma therapy, although resistance due to mutations remains a concern. Further clinical trials, including combination therapies with immunotherapy, are recommended to explore the full potential of these inhibitors in treating melanoma.